Oral UFT and leucovorin in patients with advanced gastric carcinoma

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Thirty-nine patients with locally advanced or metastatic gastric carcinoma received oral UFT (tegafur and uracil) plus leucovorin. Treatment consisted of UFT 360 mg/m2/day plus leucovorin 25 mg/m2/day, given orally in divded daily doses for 21 days followed by a 7-day rest period. The median age of the patients was 64 years, and the median World Health Organization performance status was 2. Patients received a median of two courses of treatment (range, 1 to 25). Among 37 evaluable patients, two patients achieved a complete response, and eight had partial responses, for an overall response rate of 27% (95% confidence interval, 15.4% to 42.9%). Stable disease was reported in 12 patients (32%) and another 15 showed disease progression. The median duration of response was 30 weeks, and the median duration of survival was also 30 weeks (range, 8 to 111). All patients were evaluable for toxicity. Significant toxicity (World Health Organization grade 3 or 4) included diarrhea in seven patients (18%), oral mucositis in six (15%), and nausea/vomiting in six patients. We conclude that oral UFT plus leucovorin, an outpatient regimen, has favorable activity in patients with gastric carcinoma and has tolerable toxicities.

Original languageEnglish
Pages (from-to)119-123
Number of pages5
JournalOncology
Volume11
Issue number9 SUPPL. 10
Publication statusPublished - 1997 Nov 13

Fingerprint

Leucovorin
Stomach
Carcinoma
Tegafur
Stomatitis
Uracil
Nausea
Vomiting
Disease Progression
Diarrhea
Outpatients
Confidence Intervals
Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Oral UFT and leucovorin in patients with advanced gastric carcinoma. / Kim, Yeul Hong.

In: Oncology, Vol. 11, No. 9 SUPPL. 10, 13.11.1997, p. 119-123.

Research output: Contribution to journalArticle

@article{f173003263c54492b5dfb67079b690c5,
title = "Oral UFT and leucovorin in patients with advanced gastric carcinoma",
abstract = "Thirty-nine patients with locally advanced or metastatic gastric carcinoma received oral UFT (tegafur and uracil) plus leucovorin. Treatment consisted of UFT 360 mg/m2/day plus leucovorin 25 mg/m2/day, given orally in divded daily doses for 21 days followed by a 7-day rest period. The median age of the patients was 64 years, and the median World Health Organization performance status was 2. Patients received a median of two courses of treatment (range, 1 to 25). Among 37 evaluable patients, two patients achieved a complete response, and eight had partial responses, for an overall response rate of 27{\%} (95{\%} confidence interval, 15.4{\%} to 42.9{\%}). Stable disease was reported in 12 patients (32{\%}) and another 15 showed disease progression. The median duration of response was 30 weeks, and the median duration of survival was also 30 weeks (range, 8 to 111). All patients were evaluable for toxicity. Significant toxicity (World Health Organization grade 3 or 4) included diarrhea in seven patients (18{\%}), oral mucositis in six (15{\%}), and nausea/vomiting in six patients. We conclude that oral UFT plus leucovorin, an outpatient regimen, has favorable activity in patients with gastric carcinoma and has tolerable toxicities.",
author = "Kim, {Yeul Hong}",
year = "1997",
month = "11",
day = "13",
language = "English",
volume = "11",
pages = "119--123",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "9 SUPPL. 10",

}

TY - JOUR

T1 - Oral UFT and leucovorin in patients with advanced gastric carcinoma

AU - Kim, Yeul Hong

PY - 1997/11/13

Y1 - 1997/11/13

N2 - Thirty-nine patients with locally advanced or metastatic gastric carcinoma received oral UFT (tegafur and uracil) plus leucovorin. Treatment consisted of UFT 360 mg/m2/day plus leucovorin 25 mg/m2/day, given orally in divded daily doses for 21 days followed by a 7-day rest period. The median age of the patients was 64 years, and the median World Health Organization performance status was 2. Patients received a median of two courses of treatment (range, 1 to 25). Among 37 evaluable patients, two patients achieved a complete response, and eight had partial responses, for an overall response rate of 27% (95% confidence interval, 15.4% to 42.9%). Stable disease was reported in 12 patients (32%) and another 15 showed disease progression. The median duration of response was 30 weeks, and the median duration of survival was also 30 weeks (range, 8 to 111). All patients were evaluable for toxicity. Significant toxicity (World Health Organization grade 3 or 4) included diarrhea in seven patients (18%), oral mucositis in six (15%), and nausea/vomiting in six patients. We conclude that oral UFT plus leucovorin, an outpatient regimen, has favorable activity in patients with gastric carcinoma and has tolerable toxicities.

AB - Thirty-nine patients with locally advanced or metastatic gastric carcinoma received oral UFT (tegafur and uracil) plus leucovorin. Treatment consisted of UFT 360 mg/m2/day plus leucovorin 25 mg/m2/day, given orally in divded daily doses for 21 days followed by a 7-day rest period. The median age of the patients was 64 years, and the median World Health Organization performance status was 2. Patients received a median of two courses of treatment (range, 1 to 25). Among 37 evaluable patients, two patients achieved a complete response, and eight had partial responses, for an overall response rate of 27% (95% confidence interval, 15.4% to 42.9%). Stable disease was reported in 12 patients (32%) and another 15 showed disease progression. The median duration of response was 30 weeks, and the median duration of survival was also 30 weeks (range, 8 to 111). All patients were evaluable for toxicity. Significant toxicity (World Health Organization grade 3 or 4) included diarrhea in seven patients (18%), oral mucositis in six (15%), and nausea/vomiting in six patients. We conclude that oral UFT plus leucovorin, an outpatient regimen, has favorable activity in patients with gastric carcinoma and has tolerable toxicities.

UR - http://www.scopus.com/inward/record.url?scp=0031228043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031228043&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 119

EP - 123

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 9 SUPPL. 10

ER -